Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma

Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of me...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 64; no. 2; pp. 473 - 487
Main Authors Kai, Alan Ka‐Lun, Chan, Lo Kong, Lo, Regina Cheuk‐Lam, Lee, Joyce Man‐Fong, Wong, Carmen Chak‐Lui, Wong, Jack Chun‐Ming, Ng, Irene Oi‐Lin
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.08.2016
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473‐487)
AbstractList Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (H epatology 2016;64:473‐487)
Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3 alpha . Conclusion: TIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1 alpha /miR-210/HIF-3 alpha . TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016; 64:473-487)
Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473‐487)
UNLABELLEDCancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3α.CONCLUSIONTIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1α/miR-210/HIF-3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473-487).
Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3α. TIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1α/miR-210/HIF-3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473-487).
Author Lee, Joyce Man‐Fong
Wong, Carmen Chak‐Lui
Wong, Jack Chun‐Ming
Kai, Alan Ka‐Lun
Ng, Irene Oi‐Lin
Chan, Lo Kong
Lo, Regina Cheuk‐Lam
AuthorAffiliation 1 State Key Laboratory for Liver Research The University of Hong Kong Hong Kong
2 Department of Pathology The University of Hong Kong Hong Kong
AuthorAffiliation_xml – name: 2 Department of Pathology The University of Hong Kong Hong Kong
– name: 1 State Key Laboratory for Liver Research The University of Hong Kong Hong Kong
Author_xml – sequence: 1
  givenname: Alan Ka‐Lun
  surname: Kai
  fullname: Kai, Alan Ka‐Lun
  organization: The University of Hong Kong
– sequence: 2
  givenname: Lo Kong
  surname: Chan
  fullname: Chan, Lo Kong
  organization: The University of Hong Kong
– sequence: 3
  givenname: Regina Cheuk‐Lam
  surname: Lo
  fullname: Lo, Regina Cheuk‐Lam
  organization: The University of Hong Kong
– sequence: 4
  givenname: Joyce Man‐Fong
  surname: Lee
  fullname: Lee, Joyce Man‐Fong
  organization: The University of Hong Kong
– sequence: 5
  givenname: Carmen Chak‐Lui
  surname: Wong
  fullname: Wong, Carmen Chak‐Lui
  organization: The University of Hong Kong
– sequence: 6
  givenname: Jack Chun‐Ming
  surname: Wong
  fullname: Wong, Jack Chun‐Ming
  organization: The University of Hong Kong
– sequence: 7
  givenname: Irene Oi‐Lin
  surname: Ng
  fullname: Ng, Irene Oi‐Lin
  organization: The University of Hong Kong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27018975$$D View this record in MEDLINE/PubMed
BookMark eNqNkt9qFDEUxoNU7LZ64QtIwBu92G7-TJKZG0Fq6y5ULFKvQ5I9002dSdbMjGXv-gTFV-mL9CF8ErPdtWhBEQIJ5_y-j3NOzh7aCTEAQs8pOaCEsMkClgesFEo9QiMqmBpzLsgOGhGmyLiivNpFe113QQipClY-Qbs5TstKiRG6fhcvw4-r7wnOh8b0PgYca3w2-3DKsF3h6ew4J-ntzaT1n_KLUTLZxPjtDd6KYlrhGmBujfuCnU9u8D2GsDDBQYfd-kq4hd50-fgO-4BzxVnnoGmyQcpMcj7E1jxFj2vTdPBse--jz8dHZ4fT8cnH97PDtydjJwqpxtTZohZg53xeWULmQlqhBHVGlmBtRRkDaYHWxhIJsna530Jap3jFlFMAfB-92fguB9vC3EHok2n0MvnWpJWOxus_M8Ev9Hn8pgVRBSc8G7zaGqT4dYCu163v1v2YAHHoNC0pLctKCPEfKJFFIWS5Rl8-QC_ikEKehGaSSsFpwdfUi9-Lv6_6169m4PUGcCl2XYL6HqFErzdG5_nru43J7OQB63x_twi5b9_8S3HpG1j93VpPj043ip9_H9gG
CitedBy_id crossref_primary_10_1007_s00018_018_2941_6
crossref_primary_10_1002_cam4_1618
crossref_primary_10_1007_s11033_023_08852_0
crossref_primary_10_1002_ijc_30730
crossref_primary_10_3390_cancers11121906
crossref_primary_10_1007_s10585_018_9930_x
crossref_primary_10_1016_j_compbiomed_2024_108867
crossref_primary_10_1186_s12906_024_04569_0
crossref_primary_10_1016_j_nantod_2020_100934
crossref_primary_10_18632_aging_101587
crossref_primary_10_18632_oncotarget_15968
crossref_primary_10_1016_j_canlet_2024_217145
crossref_primary_10_2174_0929867329666220829095334
crossref_primary_10_1016_j_biopha_2018_01_162
crossref_primary_10_1371_journal_pone_0199827
crossref_primary_10_3390_ijms21134624
crossref_primary_10_3389_fphar_2022_991052
crossref_primary_10_1002_hep_31225
crossref_primary_10_1158_1541_7786_MCR_17_0256
crossref_primary_10_1002_hep_31221
crossref_primary_10_1002_jcp_29507
crossref_primary_10_1038_s41419_018_0616_8
crossref_primary_10_1155_2021_6699910
crossref_primary_10_1186_s13046_020_01733_5
crossref_primary_10_1002_1878_0261_13260
crossref_primary_10_1155_2022_3632764
crossref_primary_10_3724_abbs_2023231
crossref_primary_10_1002_mc_23585
crossref_primary_10_1002_jcp_29289
crossref_primary_10_3389_fcell_2022_1012254
crossref_primary_10_1016_j_cej_2022_138421
crossref_primary_10_1016_j_lfs_2021_119465
crossref_primary_10_1080_17474124_2017_1309281
crossref_primary_10_1016_j_omtn_2018_02_014
crossref_primary_10_1016_j_toxlet_2021_12_014
crossref_primary_10_1016_j_ejcb_2024_151386
crossref_primary_10_3390_cancers10120471
crossref_primary_10_1016_j_bbrc_2023_04_055
crossref_primary_10_1259_bjr_20190198
crossref_primary_10_1186_s12986_018_0323_6
crossref_primary_10_14814_phy2_15810
crossref_primary_10_3390_cancers15235553
crossref_primary_10_1038_s41388_023_02869_2
crossref_primary_10_1124_mol_116_107706
crossref_primary_10_3390_cells12242851
crossref_primary_10_1186_s12885_019_6429_z
crossref_primary_10_1038_s41401_018_0014_x
crossref_primary_10_1007_s10456_018_9600_2
crossref_primary_10_1631_jzus_B1900343
crossref_primary_10_2147_CMAR_S222878
crossref_primary_10_1016_j_cyto_2022_155917
crossref_primary_10_1016_j_yexcr_2021_112804
crossref_primary_10_1007_s10585_023_10224_8
crossref_primary_10_1186_s12943_021_01488_3
crossref_primary_10_3390_cells9010114
crossref_primary_10_3892_ol_2017_7349
crossref_primary_10_1007_s11523_018_0555_4
crossref_primary_10_1186_s12943_021_01440_5
crossref_primary_10_18632_oncotarget_16356
crossref_primary_10_1186_s12943_017_0688_6
crossref_primary_10_1515_hmbci_2023_0012
crossref_primary_10_1155_2024_5523283
crossref_primary_10_1002_1878_0261_12657
crossref_primary_10_3389_fmed_2021_686885
crossref_primary_10_1038_s41389_017_0011_9
crossref_primary_10_1021_acsomega_4c08947
crossref_primary_10_1016_j_critrevonc_2021_103236
crossref_primary_10_1111_jcmm_17808
crossref_primary_10_18632_oncotarget_20883
crossref_primary_10_1007_s12013_024_01624_y
crossref_primary_10_14336_AD_2021_0315
crossref_primary_10_3390_cells10082161
crossref_primary_10_1016_j_drudis_2018_05_003
crossref_primary_10_1155_2020_1964219
crossref_primary_10_1007_s10565_022_09747_9
crossref_primary_10_1016_j_jpha_2024_101133
crossref_primary_10_3390_pharmaceutics15071887
crossref_primary_10_1158_1078_0432_CCR_17_2725
crossref_primary_10_1021_acs_biomac_8b00107
crossref_primary_10_3389_fgene_2020_580138
crossref_primary_10_1186_s12935_020_01719_5
crossref_primary_10_1186_s13046_020_01768_8
crossref_primary_10_1016_j_canlet_2021_11_006
crossref_primary_10_3389_fonc_2020_01620
crossref_primary_10_1155_2022_5262963
crossref_primary_10_3389_fonc_2021_605894
crossref_primary_10_1155_2020_2415324
crossref_primary_10_1016_j_clinre_2023_102077
crossref_primary_10_1007_s10930_017_9707_0
Cites_doi 10.1016/j.molcel.2010.07.023
10.1038/nrm3141
10.1097/00006676-200410000-00008
10.1002/hep.24614
10.1016/S0140-6736(02)08649-X
10.1038/nature06174
10.1016/j.semcancer.2010.05.002
10.1038/nrg2101
10.1096/fj.05-3788com
10.1038/nrclinonc.2010.173
10.1002/hep.25512
10.1242/jcs.00063
10.1007/s10555-007-9105-8
10.1053/j.gastro.2010.10.006
10.1038/nature06487
10.1101/gad.1950610
10.1002/hep.25987
10.1016/S0092-8674(00)81235-0
10.4161/cc.6.22.4947
10.1002/ijc.1440
10.3322/canjclin.55.2.74
10.1002/path.3995
10.1002/hep.27320
10.1089/hum.2008.164
10.1002/hep.25979
10.1016/j.cell.2011.10.043
10.4161/auto.5656
10.1016/j.cell.2010.03.015
10.1053/jhep.2002.33156
10.1038/35107085
ContentType Journal Article
Copyright 2016 The Authors. H published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
2016. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2016 The Authors. H published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
– notice: 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
– notice: 2016. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
H94
K9.
7X8
5PM
DOI 10.1002/hep.28577
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList
AIDS and Cancer Research Abstracts
CrossRef

MEDLINE - Academic
AIDS and Cancer Research Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Kai et al
EISSN 1527-3350
EndPage 487
ExternalDocumentID PMC5074303
27018975
10_1002_hep_28577
HEP28577
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: S.K. Yee Medical Research Fund 2011
– fundername: University Development Fund of The University of Hong Kong
– fundername: Lee Shiu Family Foundation
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OB
1OC
1ZS
1~5
24P
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AALRI
AANHP
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABLJU
ABMAC
ABOCM
ABPVW
ABWVN
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACLDA
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AECAP
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFGKR
AFPWT
AFUWQ
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RGB
RIG
RIWAO
RJQFR
ROL
RPZ
RWI
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ABJNI
ACZKN
AFNMH
AGQPQ
AHQVU
CITATION
MEWTI
WXSBR
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
AAMMB
ADSXY
AEFGJ
AGXDD
AIDQK
AIDYY
H94
K9.
7X8
5PM
ID FETCH-LOGICAL-c5467-1cb4f5ebd3d9b00d56b5751ca68ebb9122e6be1fab06e6fc27046bc73927c7ee3
IEDL.DBID DR2
ISSN 0270-9139
IngestDate Thu Aug 21 13:56:50 EDT 2025
Fri Jul 11 00:20:19 EDT 2025
Fri Jul 11 08:51:24 EDT 2025
Wed Aug 13 09:02:30 EDT 2025
Thu Apr 03 07:02:56 EDT 2025
Tue Jul 01 03:33:45 EDT 2025
Thu Apr 24 22:52:01 EDT 2025
Wed Jan 22 16:53:39 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Attribution-NonCommercial
2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5467-1cb4f5ebd3d9b00d56b5751ca68ebb9122e6be1fab06e6fc27046bc73927c7ee3
Notes Potential conflict of interest: Nothing to report.
The study was funded by the S.K. Yee Medical Research Fund 2011, University Development Fund of The University of Hong Kong, and Lee Shiu Family Foundation. I.O.L. Ng is Loke Yew Professor in Pathology.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28577
PMID 27018975
PQID 2616531435
PQPubID 996352
PageCount 15
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5074303
proquest_miscellaneous_1811889555
proquest_miscellaneous_1806445685
proquest_journals_2616531435
pubmed_primary_27018975
crossref_primary_10_1002_hep_28577
crossref_citationtrail_10_1002_hep_28577
wiley_primary_10_1002_hep_28577_HEP28577
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2016
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 08
  year: 2016
  text: August 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Hepatology (Baltimore, Md.)
PublicationTitleAlternate Hepatology
PublicationYear 2016
Publisher Wolters Kluwer Health, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wolters Kluwer Health, Inc
– name: John Wiley and Sons Inc
References 2001; 94
2007; 449
2009; 20
2004; 29
2010; 39
2002; 35
2002; 359
2010; 141
2002; 115
2011; 54
2011; 12
2008; 4
2008; 1
2014; 60
2012; 55
2012; 227
2011; 8
2005; 2005
2011; 147
2010; 20
2005; 19
2010; 24
2013; 57
2008; 27
2007; 8
2007; 6
1996; 85
1998; 7
2011; 140
2008; 451
2005; 55
2001; 414
(hep28577-bib-0033-20241017) 2009; 20
(hep28577-bib-0032-20241017) 2002; 35
(hep28577-bib-0022-20241017) 2001; 414
(hep28577-bib-0025-20241017) 2011; 54
(hep28577-bib-0009-20241017) 2007; 449
(hep28577-bib-0010-20241017) 2008; 451
(hep28577-bib-0018-20241017) 2010; 24
(hep28577-bib-0024-20241017) 2007; 6
(hep28577-bib-0012-20241017) 2013; 57
(hep28577-bib-0030-20241017) 2012; 227
(hep28577-bib-0004-20241017) 2008; 1
(hep28577-bib-0017-20241017) 2011; 147
(hep28577-bib-0026-20241017) 2004; 29
(hep28577-bib-0020-20241017) 2012; 55
(hep28577-bib-0003-20241017) 2007; 8
(hep28577-bib-0015-20241017) 2013; 57
(hep28577-bib-0007-20241017) 2008; 27
(hep28577-bib-0002-20241017) 2005; 55
(hep28577-bib-0031-20241017) 2002; 359
(hep28577-bib-0029-20241017) 2010; 20
(hep28577-bib-0006-20241017) 2002; 115
(hep28577-bib-0019-20241017) 2010; 39
(hep28577-bib-0027-20241017) 2008; 4
(hep28577-bib-0005-20241017) 2010; 141
(hep28577-bib-0008-20241017) 2011; 8
(hep28577-bib-0011-20241017) 2011; 140
(hep28577-bib-0023-20241017) 2005; 19
(hep28577-bib-0001-20241017) 2001; 94
(hep28577-bib-0013-20241017) 2014; 60
(hep28577-bib-0014-20241017) 2005; 2005
(hep28577-bib-0016-20241017) 2011; 12
(hep28577-bib-0028-20241017) 1996; 85
(hep28577-bib-0021-20241017) 1998; 7
22262409 - J Pathol. 2012 Jul;227(3):275-85
20371345 - Cell. 2010 Apr 2;141(1):52-67
8646777 - Cell. 1996 May 31;85(5):683-93
17440531 - Nat Rev Genet. 2007 May;8(5):341-52
18612141 - Sci Signal. 2008 Jul 08;1(27):re6
25048396 - Hepatology. 2014 Nov;60(5):1645-58
16126907 - FASEB J. 2005 Sep;19(11):1396-406
22144109 - Hepatology. 2011 Dec;54(6):2064-75
22135159 - Hepatology. 2012 May;55(5):1453-61
17998805 - Cell Cycle. 2007 Nov 15;6(22):2810-6
22153071 - Cell. 2011 Dec 9;147(6):1233-47
16234508 - Sci STKE. 2005 Oct 18;2005(306):re12
12235282 - J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27
15367889 - Pancreas. 2004 Oct;29(3):225-30
18185580 - Nature. 2008 Jan 10;451(7175):147-52
22829315 - Hepatology. 2013 Jan;57(1):152-61
11734856 - Nature. 2001 Nov 29;414(6863):550-4
21697900 - Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
20797623 - Mol Cell. 2010 Aug 27;39(4):493-506
21045789 - Nat Rev Clin Oncol. 2011 Feb;8(2):75-84
21159816 - Genes Dev. 2010 Dec 15;24(24):2754-9
22821423 - Hepatology. 2013 Jan;57(1):131-9
11981766 - Hepatology. 2002 May;35(5):1164-71
15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
17898713 - Nature. 2007 Oct 11;449(7163):682-8
11668491 - Int J Cancer. 2001 Oct 15;94(2):153-6
12049862 - Lancet. 2002 May 18;359(9319):1734-9
18253086 - Autophagy. 2008 Apr;4(3):388-90
18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66
9840812 - Gene Expr. 1998;7(3):205-13
20951699 - Gastroenterology. 2011 Jan;140(1):322-31
20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8
19327024 - Hum Gene Ther. 2009 Apr;20(4):314-24
References_xml – volume: 451
  start-page: 147
  year: 2008
  end-page: 152
  article-title: Endogenous human microRNAs that suppress breast cancer metastasis
  publication-title: Nature
– volume: 20
  start-page: 314
  year: 2009
  end-page: 324
  article-title: Antisense hypoxia‐inducible factor‐1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats
  publication-title: Hum Gene Ther
– volume: 57
  start-page: 152
  year: 2013
  end-page: 161
  article-title: RhoE is frequently down‐regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho‐kinase/myosin phosphatase target pathway
  publication-title: Hepatology
– volume: 54
  start-page: 2064
  year: 2011
  end-page: 2075
  article-title: Hypoxia‐inducible microRNA‐210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 1
  start-page: re6
  year: 2008
  article-title: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase‐independent biological activities
  publication-title: Sci Signal
– volume: 359
  start-page: 1734
  year: 2002
  end-page: 1739
  article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
  publication-title: Lancet
– volume: 8
  start-page: 75
  year: 2011
  end-page: 84
  article-title: Metastamirs: a stepping stone towards improved cancer management
  publication-title: Nat Rev Clin Oncol
– volume: 449
  start-page: 682
  year: 2007
  end-page: 688
  article-title: Tumour invasion and metastasis initiated by microRNA‐10b in breast cancer
  publication-title: Nature
– volume: 115
  start-page: 3719
  year: 2002
  end-page: 3727
  article-title: Metalloproteinase inhibitors: biological actions and therapeutic opportunities
  publication-title: J Cell Sci
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
– volume: 140
  start-page: 322
  year: 2011
  end-page: 331
  article-title: The microRNA miR‐139 suppresses metastasis and progression of hepatocellular carcinoma by down‐regulating Rho‐kinase 2
  publication-title: Gastroenterology
– volume: 19
  start-page: 1396
  year: 2005
  end-page: 1406
  article-title: Human HIF‐3alpha4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma
  publication-title: FASEB J
– volume: 4
  start-page: 388
  year: 2008
  end-page: 390
  article-title: A novel mammalian trans‐membrane protein reveals an alternative initiation pathway for autophagy
  publication-title: Autophagy
– volume: 12
  start-page: 413
  year: 2011
  end-page: 426
  article-title: The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function
  publication-title: Nat Rev Mol Cell Biol
– volume: 60
  start-page: 1645
  year: 2014
  end-page: 1658
  article-title: Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 8
  start-page: 341
  year: 2007
  end-page: 352
  article-title: Genetic determinants of cancer metastasis
  publication-title: Nat Rev Genet
– volume: 35
  start-page: 1164
  year: 2002
  end-page: 1171
  article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
  publication-title: Hepatology
– volume: 414
  start-page: 550
  year: 2001
  end-page: 554
  article-title: Inhibitory PAS domain protein is a negative regulator of hypoxia‐inducible gene expression
  publication-title: Nature
– volume: 94
  start-page: 153
  year: 2001
  end-page: 156
  article-title: Estimating the world cancer burden: Globocan 2000
  publication-title: Int J Cancer
– volume: 20
  start-page: 161
  year: 2010
  end-page: 168
  article-title: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion
  publication-title: Semin Cancer Biol
– volume: 57
  start-page: 131
  year: 2013
  end-page: 139
  article-title: C‐terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C‐Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma
  publication-title: Hepatology
– volume: 55
  start-page: 1453
  year: 2012
  end-page: 1461
  article-title: Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis
  publication-title: Hepatology
– volume: 39
  start-page: 493
  year: 2010
  end-page: 506
  article-title: STAT3 activation of miR‐21 and miR‐181b‐1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
  publication-title: Mol Cell
– volume: 2005
  start-page: re12
  year: 2005
  article-title: Integration of oxygen signaling at the consensus HRE
  publication-title: Sci STKE
– volume: 27
  start-page: 57
  year: 2008
  end-page: 66
  article-title: The tumor microenvironment: regulation by MMP‐independent effects of tissue inhibitor of metalloproteinases‐2
  publication-title: Cancer Metastasis Rev
– volume: 24
  start-page: 2754
  year: 2010
  end-page: 2759
  article-title: Repression of the miR‐143/145 cluster by oncogenic Ras initiates a tumor‐promoting feed‐forward pathway
  publication-title: Genes Dev
– volume: 141
  start-page: 52
  year: 2010
  end-page: 67
  article-title: Matrix metalloproteinases: regulators of the tumor microenvironment
  publication-title: Cell
– volume: 147
  start-page: 1233
  year: 2011
  end-page: 1247
  article-title: An HNF4alpha‐miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis
  publication-title: Cell
– volume: 29
  start-page: 225
  year: 2004
  end-page: 230
  article-title: Expression of vacuole membrane protein 1 (VMP1) in spontaneous chronic pancreatitis in the WBN/Kob rat
  publication-title: Pancreas
– volume: 6
  start-page: 2810
  year: 2007
  end-page: 2816
  article-title: Dominant‐negative HIF‐3 alpha 4 suppresses VHL‐null renal cell carcinoma progression
  publication-title: Cell Cycle
– volume: 227
  start-page: 275
  year: 2012
  end-page: 285
  article-title: In hepatocellular carcinoma miR‐519d is up‐regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2
  publication-title: J Pathol
– volume: 85
  start-page: 683
  year: 1996
  end-page: 693
  article-title: Localization of matrix metalloproteinase MMP‐2 to the surface of invasive cells by interaction with integrin alpha v beta 3
  publication-title: Cell
– volume: 7
  start-page: 205
  year: 1998
  end-page: 213
  article-title: Molecular characterization and chromosomal localization of a third alpha‐class hypoxia inducible factor subunit, HIF3alpha
  publication-title: Gene Expr
– volume: 39
  start-page: 493
  year: 2010
  ident: hep28577-bib-0019-20241017
  article-title: STAT3 activation of miR‐21 and miR‐181b‐1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2010.07.023
– volume: 7
  start-page: 205
  year: 1998
  ident: hep28577-bib-0021-20241017
  article-title: Molecular characterization and chromosomal localization of a third alpha‐class hypoxia inducible factor subunit, HIF3alpha
  publication-title: Gene Expr
– volume: 12
  start-page: 413
  year: 2011
  ident: hep28577-bib-0016-20241017
  article-title: The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm3141
– volume: 29
  start-page: 225
  year: 2004
  ident: hep28577-bib-0026-20241017
  article-title: Expression of vacuole membrane protein 1 (VMP1) in spontaneous chronic pancreatitis in the WBN/Kob rat
  publication-title: Pancreas
  doi: 10.1097/00006676-200410000-00008
– volume: 54
  start-page: 2064
  year: 2011
  ident: hep28577-bib-0025-20241017
  article-title: Hypoxia‐inducible microRNA‐210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.24614
– volume: 359
  start-page: 1734
  year: 2002
  ident: hep28577-bib-0031-20241017
  article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08649-X
– volume: 449
  start-page: 682
  year: 2007
  ident: hep28577-bib-0009-20241017
  article-title: Tumour invasion and metastasis initiated by microRNA‐10b in breast cancer
  publication-title: Nature
  doi: 10.1038/nature06174
– volume: 20
  start-page: 161
  year: 2010
  ident: hep28577-bib-0029-20241017
  article-title: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2010.05.002
– volume: 8
  start-page: 341
  year: 2007
  ident: hep28577-bib-0003-20241017
  article-title: Genetic determinants of cancer metastasis
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2101
– volume: 19
  start-page: 1396
  year: 2005
  ident: hep28577-bib-0023-20241017
  article-title: Human HIF‐3alpha4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma
  publication-title: FASEB J
  doi: 10.1096/fj.05-3788com
– volume: 2005
  start-page: re12
  year: 2005
  ident: hep28577-bib-0014-20241017
  article-title: Integration of oxygen signaling at the consensus HRE
  publication-title: Sci STKE
– volume: 8
  start-page: 75
  year: 2011
  ident: hep28577-bib-0008-20241017
  article-title: Metastamirs: a stepping stone towards improved cancer management
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2010.173
– volume: 55
  start-page: 1453
  year: 2012
  ident: hep28577-bib-0020-20241017
  article-title: Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis
  publication-title: Hepatology
  doi: 10.1002/hep.25512
– volume: 115
  start-page: 3719
  year: 2002
  ident: hep28577-bib-0006-20241017
  article-title: Metalloproteinase inhibitors: biological actions and therapeutic opportunities
  publication-title: J Cell Sci
  doi: 10.1242/jcs.00063
– volume: 27
  start-page: 57
  year: 2008
  ident: hep28577-bib-0007-20241017
  article-title: The tumor microenvironment: regulation by MMP‐independent effects of tissue inhibitor of metalloproteinases‐2
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-007-9105-8
– volume: 140
  start-page: 322
  year: 2011
  ident: hep28577-bib-0011-20241017
  article-title: The microRNA miR‐139 suppresses metastasis and progression of hepatocellular carcinoma by down‐regulating Rho‐kinase 2
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2010.10.006
– volume: 451
  start-page: 147
  year: 2008
  ident: hep28577-bib-0010-20241017
  article-title: Endogenous human microRNAs that suppress breast cancer metastasis
  publication-title: Nature
  doi: 10.1038/nature06487
– volume: 24
  start-page: 2754
  year: 2010
  ident: hep28577-bib-0018-20241017
  article-title: Repression of the miR‐143/145 cluster by oncogenic Ras initiates a tumor‐promoting feed‐forward pathway
  publication-title: Genes Dev
  doi: 10.1101/gad.1950610
– volume: 57
  start-page: 152
  year: 2013
  ident: hep28577-bib-0012-20241017
  article-title: RhoE is frequently down‐regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho‐kinase/myosin phosphatase target pathway
  publication-title: Hepatology
  doi: 10.1002/hep.25987
– volume: 85
  start-page: 683
  year: 1996
  ident: hep28577-bib-0028-20241017
  article-title: Localization of matrix metalloproteinase MMP‐2 to the surface of invasive cells by interaction with integrin alpha v beta 3
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81235-0
– volume: 6
  start-page: 2810
  year: 2007
  ident: hep28577-bib-0024-20241017
  article-title: Dominant‐negative HIF‐3 alpha 4 suppresses VHL‐null renal cell carcinoma progression
  publication-title: Cell Cycle
  doi: 10.4161/cc.6.22.4947
– volume: 94
  start-page: 153
  year: 2001
  ident: hep28577-bib-0001-20241017
  article-title: Estimating the world cancer burden: Globocan 2000
  publication-title: Int J Cancer
  doi: 10.1002/ijc.1440
– volume: 55
  start-page: 74
  year: 2005
  ident: hep28577-bib-0002-20241017
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.55.2.74
– volume: 227
  start-page: 275
  year: 2012
  ident: hep28577-bib-0030-20241017
  article-title: In hepatocellular carcinoma miR‐519d is up‐regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2
  publication-title: J Pathol
  doi: 10.1002/path.3995
– volume: 1
  start-page: re6
  year: 2008
  ident: hep28577-bib-0004-20241017
  article-title: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase‐independent biological activities
  publication-title: Sci Signal
– volume: 60
  start-page: 1645
  year: 2014
  ident: hep28577-bib-0013-20241017
  article-title: Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.27320
– volume: 20
  start-page: 314
  year: 2009
  ident: hep28577-bib-0033-20241017
  article-title: Antisense hypoxia‐inducible factor‐1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats
  publication-title: Hum Gene Ther
  doi: 10.1089/hum.2008.164
– volume: 57
  start-page: 131
  year: 2013
  ident: hep28577-bib-0015-20241017
  article-title: C‐terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C‐Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.25979
– volume: 147
  start-page: 1233
  year: 2011
  ident: hep28577-bib-0017-20241017
  article-title: An HNF4alpha‐miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis
  publication-title: Cell
  doi: 10.1016/j.cell.2011.10.043
– volume: 4
  start-page: 388
  year: 2008
  ident: hep28577-bib-0027-20241017
  article-title: A novel mammalian trans‐membrane protein reveals an alternative initiation pathway for autophagy
  publication-title: Autophagy
  doi: 10.4161/auto.5656
– volume: 141
  start-page: 52
  year: 2010
  ident: hep28577-bib-0005-20241017
  article-title: Matrix metalloproteinases: regulators of the tumor microenvironment
  publication-title: Cell
  doi: 10.1016/j.cell.2010.03.015
– volume: 35
  start-page: 1164
  year: 2002
  ident: hep28577-bib-0032-20241017
  article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1053/jhep.2002.33156
– volume: 414
  start-page: 550
  year: 2001
  ident: hep28577-bib-0022-20241017
  article-title: Inhibitory PAS domain protein is a negative regulator of hypoxia‐inducible gene expression
  publication-title: Nature
  doi: 10.1038/35107085
– reference: 21159816 - Genes Dev. 2010 Dec 15;24(24):2754-9
– reference: 20371345 - Cell. 2010 Apr 2;141(1):52-67
– reference: 20951699 - Gastroenterology. 2011 Jan;140(1):322-31
– reference: 11981766 - Hepatology. 2002 May;35(5):1164-71
– reference: 22262409 - J Pathol. 2012 Jul;227(3):275-85
– reference: 16234508 - Sci STKE. 2005 Oct 18;2005(306):re12
– reference: 19327024 - Hum Gene Ther. 2009 Apr;20(4):314-24
– reference: 15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
– reference: 20797623 - Mol Cell. 2010 Aug 27;39(4):493-506
– reference: 22829315 - Hepatology. 2013 Jan;57(1):152-61
– reference: 12049862 - Lancet. 2002 May 18;359(9319):1734-9
– reference: 11734856 - Nature. 2001 Nov 29;414(6863):550-4
– reference: 18185580 - Nature. 2008 Jan 10;451(7175):147-52
– reference: 9840812 - Gene Expr. 1998;7(3):205-13
– reference: 18253086 - Autophagy. 2008 Apr;4(3):388-90
– reference: 17440531 - Nat Rev Genet. 2007 May;8(5):341-52
– reference: 22135159 - Hepatology. 2012 May;55(5):1453-61
– reference: 15367889 - Pancreas. 2004 Oct;29(3):225-30
– reference: 25048396 - Hepatology. 2014 Nov;60(5):1645-58
– reference: 21045789 - Nat Rev Clin Oncol. 2011 Feb;8(2):75-84
– reference: 17998805 - Cell Cycle. 2007 Nov 15;6(22):2810-6
– reference: 21697900 - Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
– reference: 22144109 - Hepatology. 2011 Dec;54(6):2064-75
– reference: 18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66
– reference: 17898713 - Nature. 2007 Oct 11;449(7163):682-8
– reference: 12235282 - J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27
– reference: 16126907 - FASEB J. 2005 Sep;19(11):1396-406
– reference: 22821423 - Hepatology. 2013 Jan;57(1):131-9
– reference: 18612141 - Sci Signal. 2008 Jul 08;1(27):re6
– reference: 20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8
– reference: 22153071 - Cell. 2011 Dec 9;147(6):1233-47
– reference: 8646777 - Cell. 1996 May 31;85(5):683-93
– reference: 11668491 - Int J Cancer. 2001 Oct 15;94(2):153-6
SSID ssj0009428
Score 2.5233903
Snippet Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a...
Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a...
UNLABELLEDCancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 473
SubjectTerms Adult
Aged
Aged, 80 and over
Animals
Basic Helix-Loop-Helix Transcription Factors - metabolism
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
Down-Regulation
Ectopic expression
Extracellular matrix
Feedback
Feedback, Physiological
Female
Gene Knockdown Techniques
Hepatobiliary Malignancies
Hepatocellular Carcinoma
Hepatology
Humans
Hypoxia
Hypoxia - metabolism
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
Invasiveness
Liver cancer
Liver Neoplasms, Experimental - metabolism
Liver Neoplasms, Experimental - pathology
Lung Neoplasms - secondary
Male
Metastases
Metastasis
Mice, Inbred BALB C
MicroRNAs - metabolism
Middle Aged
miRNA
Neoplasm Metastasis
Proteolysis
Proteolytic enzymes
Regulation
Regulatory Pathways
Tissue inhibitor of metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2 - metabolism
Tumors
Xenografts
Young Adult
Title Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28577
https://www.ncbi.nlm.nih.gov/pubmed/27018975
https://www.proquest.com/docview/2616531435
https://www.proquest.com/docview/1806445685
https://www.proquest.com/docview/1811889555
https://pubmed.ncbi.nlm.nih.gov/PMC5074303
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKD4gL_9AtpTKIA5fsJk7sJOKEoKstUtGqaqUekCLbcbRR2aRKsof2xBMgXqUv0ofgSZhxfspSQIhTongsje0Z-5t4_JmQV6n2Ax9WKkdyJh0kVHIUwHgnjLSX8dAwL7VZvh_F7Dj4cMJPNsib_ixMyw8x_HBDz7DzNTq4VPXkmjR0Yc7GLOIhniTHXC0ERIfX1FFxYO9VhajLxd3luGcVctlkqLm-Ft0AmDfzJH_Gr3YBmt4jn3rV27yT0_GqUWN98Qur43-27T652wFT-ra1pAdkwxQPye2Dbuv9Efn6HuL171--Ve3l9TCctMzo0f7BnFF1Tmf7Uyj0ri4ny_wQ3vDMTvvNv7qkXaWyOqcZLJdK6lOq80qv8oaaYoGWV1ONj4ouTSMBstZ5TfOCgo5QD7cXMF8WZCpQp1zKx-R4unf0buZ0lzk4muNk7GkVZNyo1E-RhjHlQuGWj5YiMkrFHmNGKONlUrnCiEzDuAVC6RDwW6hDY_wnZLMoC7NFqCtdljEV6zgKA4NBY-qmvkiN4RmSW43I635YE90xneOFG5-TlqOZJaB7Yvt3RF4OomctvcfvhHZ620g6D68TiDwFzF-ANkfkxVAMvok9IgtTrurEiwDwAUKN_ioDIV4Ucw4yT1tzGzSBPvCiOISScM0QBwHkBl8vKfKF5QjnCA1dH7rC2tmfG5fM9ub2ZfvfRZ-RO4AbRZsHuUM2m2plngM2a9QuucWC-a51xR-F1Dy_
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEF6VIgEX_qGBAgsCiYsTe5312gcOiDRKaFNVVSr15nrXa2K1sSs7URVOPAHiQbj0QehD8CTM-K-EAuLSAydb3nG0Gc_MfuMdf0PIy1DZXRtWKiPgLDCQUMmQAOMN4Sor4kIzKyyqfLedwV73_T7fXyFf629hSn6I5oUbekYRr9HB8YV055w1dKKP28zlQlQllZt6cQIJW_5m2IOn-4qx_sb43cCoegoYimNMsJTsRlzL0A6RDTDkjsSdBxU4rpbSsxjTjtRWFEjT0U6kmIAEUioBMEIoobUNv3uFXMUO4sjU39s9J6vyukUnV8jzTNzP9moeI5N1mqkur34XIO3FysyfEXOx5PVvkW-1sspKl8P2fCbb6uMvPJL_izZvk5sV9qZvS2e5Q1Z0cpdcG1XVBffI5156knz_9CXTH6qmZjSN6Hg42mFULuhg2IdB6-y0M4134Qw_Syqv2WentLopzRY0AkQgA3VIVZypeTyjOpmgc-VU4SGjUz0LAJXncU7jhIJO4D7cQcGSYJDJYDrpNLhP9i5FGw_IapImeo1QMzBZxKSnPFd0NebFoRnaTqg1j5C_q0Ve13bkq4rMHXuKHPklDTXzYe5-8Txb5EUjelwymPxOaL02Rr8KYrkPybUDIRoAdYs8b4Yh_KBGgkSn89y3XMC0AMLdv8pAFut6nIPMw9K-m5mADizXEzAiliy_EUD68-WRJJ4UNOgc0a9pgyoKw_7zn_MHGzvFyaN_F31Grg_Goy1_a7i9-ZjcAJjslGWf62R1ls31E4CiM_m0iACUHFy2k_wAPNCb7A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIlVcEP8ECiwIJC4m9trrtQ8cEGmUUFpFqJV6M971WLEgdmQnQrnxBIj34NQX6UPwJMzYjktUQFx6suUdW-udmd1vPONvGXueGNdzcaWyYiliiwiVLI0w3lKBcVKpQDhJXeV76I-OvXcn8mSL_Vj_C9PwQ3Qf3Mgz6vmaHHyepP1z0tApzF-JQCrVVlTuw-oLxmvV6_EAlftCiOHe0duR1W4pYBlJU4JjtJdK0ImbEBlgIn1NiQcT-wFoHTpCgK_BSWNt--CnRiiMH7VRiCKUUQAuPvcKu0rJRaofE97knOHXqzdyxTDPpnR2uKYxskW_6-rm4ncB0V4szPwdMNcr3vAGu95CVf6msa2bbAvyW2znoE3G32bfBhjB__z6vWy2s0cF8yLlR-ODieB6xUfjITY6Z6f9WfYBz-gvnuaae3bK25uKcsVTXEB1bD5xk5VmmS045FOyxYobOpR8BosYQWyVVTzLOb4m3kcJB6qgRZkSu1PM4jvs-FJ0cZdt50UO9xm3Y1ukQocmDJQHFEYmduL6CYBMie6qx16uxz0yLfc5bcHxOWpYm0WEfY9qFfXYs0503hB-_Elod628qPX5KsJY1McZDfFnjz3tmtFbaUTiHIplFTkBQkDErME_ZTDoC0IpUeZeYw9dT3AMnCBU2KI2LKUTILbwzZY8m9as4ZLAou3iUNQ29feXi0Z7k_rkwf-LPmE7k8Ewej8-3H_IriGo9JsiyV22vSiX8AiB20I_rh2Gs4-X7aG_ALNYWao
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Down%E2%80%90regulation+of+TIMP2+by+HIF%E2%80%901%CE%B1%2FmiR%E2%80%90210%2FHIF%E2%80%903%CE%B1+regulatory+feedback+circuit+enhances+cancer+metastasis+in+hepatocellular+carcinoma&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Kai%2C+Alan+Ka%E2%80%90Lun&rft.au=Chan%2C+Lo+Kong&rft.au=Lo%2C+Regina+Cheuk%E2%80%90Lam&rft.au=Lee%2C+Joyce+Man%E2%80%90Fong&rft.date=2016-08-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=64&rft.issue=2&rft.spage=473&rft.epage=487&rft_id=info:doi/10.1002%2Fhep.28577&rft_id=info%3Apmid%2F27018975&rft.externalDocID=PMC5074303
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon